Dr. Hossam Abdel Maksoud Chief Executive Officer Dr. Hossam Abdel Maksoud is the Chief Executive Officer and Founder of Maksoud Pharm Group, with over 30 years of experience in the pharmaceutical and healthcare sector. He began his career in 1993 by establishing Maksoud Pharm Inc., a network of independent retail pharmacies serving communities across the tri-state area. Building on this foundation, he launched Community Care Rx, Inc. in 2010, a long-term care pharmacy dedicated to supporting long-term care facilities across the five boroughs, Long Island, and Westchester. The company expanded further with the opening of its New Jersey location in Totowa in 2013. Following the success of Community Care Rx, Dr. Maksoud founded Community Care Consulting, providing specialized clinical expertise and consulting services to a broad range of healthcare settings. He also established Community Care Specialty Pharmacy, which supports patients with chronic and rare conditions by providing access to advanced therapies, patient guidance, and financial assistance programs. Dr. Maksoud continues to lead the organization’s strategic vision and expansion, focusing on innovative healthcare solutions that improve patient outcomes and enhance community well-being.

Our Approach Dawah Pharmaceuticals Inc. is a modern pharmaceutical company committed to expanding access to high-quality sterile injectables, ophthalmic products, and IV solutions. We follow an innovative operating model that focuses on strategic outsourcing and deep industry expertise, rather than traditional in-house manufacturing. Through partnerships with leading global Contract Manufacturing Organizations, we consistently deliver FDA-compliant medicines with efficiency, precision, and exceptional quality. Our product portfolio includes more than twenty-five essential treatments across anesthesia, oncology, critical care, and ophthalmology, addressing key needs in global healthcare. Our leadership team brings over two centuries of combined experience from top pharmaceutical institutions across the United States, Europe, and India. This strong foundation enables us to identify emerging opportunities, accelerate product development, and navigate regulatory environments with confidence and clarity. At Dawah Pharmaceuticals, we unite strategic vision, scientific expertise, and global partnerships to build a scalable and agile platform that supports patients and healthcare systems worldwide. Dawah Pharmaceuticals: Vision, Innovation, and Strategic Excellence Meeting Global Challenges Dawah Pharmaceuticals is committed to closing critical gaps in global drug supply, with a special focus on sterile dosage forms that are essential across the United States, Europe, the Middle East, and Africa. Through deep market intelligence and a strong network of world-class manufacturing partners, we deliver reliable pharmaceutical solutions that support global healthcare systems and ensure adherence to international quality standards. Innovating for the Future Our product portfolio features advanced formulations including liposomal therapies, biosimilars, and preservative-free ophthalmic products. These innovations address major therapeutic needs in oncology, antifungal treatment, and ocular care, offering improved patient outcomes, enhanced safety profiles, and greater treatment compliance. Strategic Foundations of Dawah Pharmaceuticals Outsourcing Excellence We collaborate with leading Contract Manufacturing Organizations to maintain flexibility, optimize production, and ensure delivery of high-quality, FDA-compliant medicines. Regulatory Strength Our experienced regulatory team expertly manages U.S. and global regulatory submissions, enabling efficient approval pathways and faster access to essential medications. Market Driven Strategy By continuously monitoring global healthcare trends, we identify promising therapeutic areas and adapt our development priorities to meet emerging patient and market needs. At Dawah Pharmaceuticals, we are driven by innovation, strategic partnerships, and a commitment to patient-focused excellence. Our goal is to shape the future of global healthcare and deliver meaningful value to communities around the world.

Current Market The sterile injectables market is experiencing significant growth, driven by factors such as the increasing prevalence of chronic diseases, technological advancements in drug delivery systems, and a rising demand for biologics. Global Market Outlook Market Size and Growth: The global sterile injectables market was valued at approximately USD 109.1 billion in 2024 and is projected to reach USD 230.5 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.8% during the forecast period. Business Research Insights Regional Insights North America: This region dominates the market, accounting for a significant share of global revenue. Factors contributing to this dominance include a well-established healthcare infrastructure, high adoption of advanced technologies, and an increasing prevalence of chronic diseases. Market Research Future Asia Pacific: The market in this region is expected to witness substantial growth, driven by an increasing prevalence of chronic diseases and changing lifestyles. Market Research Future Therapeutic Applications The sterile injectables market encompasses a wide range of therapeutic applications, including oncology, diabetes, cardiovascular diseases, central nervous system disorders, infectious disorders, and musculoskeletal conditions. The oncology segment is particularly significant, driven by the rising incidence of cancer and the development of innovative oncology drugs. Business Research Insights Market Drivers Rising Prevalence of Chronic Diseases: The increasing incidence of conditions such as cancer, diabetes, and cardiovascular diseases necessitates effective treatments, thereby driving the demand for sterile injectables. Market Research Future Technological Advancements: Innovations in drug delivery systems, such as prefilled syringes and auto-injectors, have improved the convenience, safety, and efficacy of sterile injectable administration, further propelling market growth. Strategic Market Research Challenges Despite the positive outlook, the market faces challenges, including stringent regulatory requirements, high manufacturing costs, and the need for maintaining strict sterility standards throughout the production process. Pharmaceutical Technology Conclusion The sterile injectables market is poised for significant growth, offering substantial opportunities for companies operating in this space. A thorough understanding of market dynamics, regional trends, and therapeutic demands is essential for capitalizing on the potential presented by this expanding market.

Egypt Signs Strategic Tripartite Partnership to Build an Integrated Medical Manufacturing Ecosystem for Regional & Global Markets Engineer Mohamed Shimi, Minister of Public Business Sector, witnessed the signing of a major tripartite partnership between Dawah Holding International (Egypt), Dawah Pharma LLC (USA), and QG Medical Devices (Qatar-Germany) at the Ministry’s headquarters in the New Administrative Capital. The ceremony was attended by the heads of the Egyptian Drug Authority (EDA) and the Unified Procurement Authority, along with senior company representatives. This agreement aims to establish a fully integrated ecosystem for the manufacturing and supply of pharmaceuticals and medical devices, reinforcing Egypt’s position as a regional hub serving Arab and global markets. It supports national efforts to localize advanced medical technologies, expand exports, and enhance regional health security The Minister emphasized that the partnership represents a key step toward modernizing the pharmaceutical industry within state-affiliated companies, supporting Egypt’s Vision 2030 to boost industrial investment, strengthen pharmaceutical security, and enhance the global competitiveness of Egyptian and Arab products Dr. Ali El-Ghamrawy, Chairman of the EDA, highlighted the Authority’s role as a strategic partner in fostering investment and localizing medical supplies manufacturing to build a strong national industry capable of competing globally Dr. Hisham Sayed Sitet, Chairman of the Unified Procurement Authority, stated that the agreement supports the creation of a unified Arab medical supply system offering high quality products at competitive prices From the private sector side, Dr. Hossam Abdel-Maksoud, Chairman and CEO of Dawah Pharma LLC, described the partnership as “a foundation for an Arab-international healthcare alliance that drives innovation and knowledge exchange.” Mr. Fahd Abdullah Malik, Vice Chairman of QG Medical Devices, said the collaboration opens new opportunities for medical manufacturing cooperation between Qatar, Egypt, and the U.S The partnership reflects a shared vision of “Health Without Borders”, with industrial and scientific projects that expand across Egypt, Africa, and the Arab region aligned with Egypt’s and Qatar’s national development goals

Pipeline Dawah Pharmaceuticals Inc. is advancing global healthcare through a robust pipeline of essential drugs in collaboration with top-tier international Contract Manufacturing Organizations (CMOs). By leveraging strategic overseas partnerships, we ensure the efficient delivery of FDA-compliant drugs that address critical therapeutic needs across a wide range of disease states. Read More Sterile Injectables Antipsychotics Help manage both chronic and acute mental health disorders to stabilize patients Paralytics Used to facilitate anesthesia and ensure patient immobilization during surgery or critical care Antibiotics Target and treat severe bacterial infections, including resistant strains Oncology Drugs Provide innovative and life-saving treatments for various types of cancer Antifungals Treat systemic and invasive fungal infections effectively. Ophthalmics Anti-inflammatory Agents: Reducing inflammation in ocular diseases. Antibiotic-Corticosteroid Combinations: Treating bacterial infections with concurrent inflammation. Antihistamines: Providing relief from allergic conjunctivitis and related ocular allergies. Bags and (TPN) Pain Management: Offering intravenous acetaminophen for effective pain and fever control. Critical Care Solutions: Including dopamine and electrolytes for emergency and intensive care applications. Nutritional Support: High-use TPN formulations for patients with impaired oral intake. Overseas Partnerships Dawah Pharmaceuticals has meticulously evaluated over 30 global CMOs and strategically partnered with two industry leaders based overseas. These partnerships are integral to our operations Optimize manufacturing costs with contributions of the sterile production cost by our selected CMOs. Activities Provided by CMOs Comprehensive Development: Formulation, process design, and analytical testing. Regulatory Preparedness: Manufacturing registration batches and compiling FDA dossiers. Stability Testing: Ensuring efficacy and safety over extended periods. Our partnerships empower Dawah Pharmaceuticals to maintain agility while delivering high-quality, FDA-compliant drugs to address critical healthcare needs. By continuously assessing market trends and patient requirements, we are committed to expanding our pipeline and improving global access to essential medications. Commitment to Excellence Here is a list of the drugs we plan to bring to the U.S. market via JV, along with their indications and projected launch years. 2026–2027 Bacterial infections (oral antibiotic) 2028 Type 2 diabetes, weight management 2028–2029 Acute heart failure, cardiac stress testing 2028–2029 Edema, congestive heart failure, hypertension 2028–2029 Short-term pain relief (injectable NSAID) 2028–2029 Gallstone dissolution, primary biliary cholangitis 2027–2028 Antiplatelet (cardiovascular diseases) 2028–2029 Sedation in intensive care and surgical settings 2028–2029 Induction of general anesthesia 2028–2029 Short-term pain relief (injectable NSAID) 2028–2029 Alzheimer’s disease 2031 Chemotherapy, autoimmune diseases (oncology)

توماس إنغالينيرا نائب الرئيس للعمليات يشغل الدكتور توماس إنغالينيرا منصب نائب الرئيس للعمليات، ويملك أكثر من 40 عامًا من الخبرة في البحث والتطوير الدوائي، مع تخصص في أشكال الجرعات القابلة للحقن. يقدم الدكتور إنغالينيرا القيادة التقنية والعلمية عبر برامج تطوير الأدوية، داعمًا المشاريع منذ مرحلة ما قبل التكوين وحتى الإنتاج التجاري الكامل. وقد شغل مناصب عليا في مؤسسات عالمية رائدة، بما في ذلك Pharmaceutics International، وBioCryst Pharmaceuticals، وParenta Pharmaceuticals، وAAI Pharma، وGenzyme، وBurroughs Wellcome، وA.H. Robins. يحمل شهادة بكالوريوس العلوم في الصيدلة ودكتوراه في الصيدلة من جامعة فيرجينيا كومنولث. وبالإضافة إلى دوره التنفيذي، يعمل الدكتور إنغالينيرا عضوًا في مجموعة الاستشارات التقنية لمؤسسة بيل وميليندا غيتس، مساهماً بخبراته في المبادرات الصحية العالمية.

Egypt’s Gypto Pharma (Medicine City) and US-based Dawa Pharmaceuticals signed a strategic alliance agreement aimed at strengthening Egypt’s pharmaceutical industry and achieving US Food and Drug Administration (FDA) qualification for Gypto Pharma’s facilities. Egyptian Prime Minister Mostafa Madbouly witnessed the signing ceremony at the government headquarters in the New Administrative Capital. The event was attended by senior officials including Minister of Planning and International Cooperation Rania Al-Mashat, Minister of Investment Hassan El Khatib, presidential health advisor Mohamed Awad Tag El-Din, the heads of the Egyptian Drug Authority (EDA) and the Unified Procurement Authority (UPA), US Ambassador to Cairo Herro Mustafa Garg, and Qatari Ambassador Tariq Ali Faraj Al-Ansari. The agreement was signed by Amr Mamdouh, Chairperson of Gypto Pharma, and Hossam Abdel Maksoud, Chairperson and CEO of Dawa Pharmaceuticals. Prime Minister Madbouly stated that Egypt’s pharmaceutical industry is a “vital field for new trade and investment and mutual growth between the United States and Egypt” and receives significant attention from President Abdel Fattah Al-Sisi. He noted the president’s support for localising vital industries, including pharmaceuticals, and seeking new export markets such as the United States. Madbouly emphasised the partnership’s importance in bringing “advanced American equipment and expertise to Egypt” and supporting efforts to gain FDA accreditation. He said this would enhance the Egyptian pharmaceutical industry’s regional and international standing and confirm its readiness to compete globally “The economic partnership between Egypt and the United States continues to grow,” Madbouly said, adding that the agreement is “another example of our two countries’ cooperation to create shared economic prosperity for both countries.” US Ambassador Garg highlighted the agreement’s significance: “The critical element in this historic agreement between Dawa Pharmaceuticals and Gypto Pharma is the provision of advanced American equipment and technology alongside know-how to expand the production of Egyptian medicines throughout Africa and the Middle East.” She added that the partnership underscores “the strength of our bilateral economic relationship and the shared prosperity it brings to both Egypt and the United States.” Mamdouh of Gypto Pharma called the partnership an “important step towards achieving the company’s vision of being a regional hub for the pharmaceutical industry,” leveraging its existing infrastructure. He noted recent successes, including partnerships with seven international firms for joint manufacturing and technology transfer, and the launch of essential medicines. “This alliance aims to invest in developing Gypto Pharma’s production capabilities, adding new lines and modern systems according to the requirements of the US Food and Drug Administration (FDA), and qualifying for export to the US market,” Mamdouh said. He stressed the alignment with state goals of encouraging investment, localising industries, and boosting exports. Abdel Maksoud of Dawa Pharmaceuticals expressed pride in the partnership, calling it a “pivotal step towards supporting innovation efforts and industrial integration in the pharmaceutical industry field.” He described Gypto Pharma as a “strategic partner with advanced industrial capabilities, and a clear vision.” Abdel Maksoud affirmed Dawa’s commitment to “transferring the necessary technical expertise and know-how to support Gypto Pharma in obtaining the qualification of the US Food and Drug Administration (FDA),” enabling US market entry and enhancing local manufacturing to global standards The statement noted the agreement aims to enhance bilateral trade and investment in pharmaceutical innovation, improve products for consumers in both countries, and boost the value of their respective biopharmaceutical industries

Strategic Partnership Signed Between Dawah Pharma LLC (USA) and Bateel Group Holding A strategic partnership agreement has been signed in Cairo between Dawah Pharma LLC (USA) and Bateel Group Holding, in the presence of key industry and government representatives. The agreement aims to upgrade pharmaceutical production lines in compliance with FDA standards and introduce new investments to support the export of Egyptian pharmaceuticals to global markets. This milestone builds on Dawah Pharma’s successful collaborations in Egypt with Gypto Pharma City and Dawah Holdi, reinforcing its commitment to enhancing the competitiveness of the Egyptian pharmaceutical industry, transferring global technologies, and strengthening Egypt’s position as a leading regional hub for pharmaceutical manufacturing and export

نيكولاس فارطانيان تطوير الشركات، المؤسس يتمتع نيكولاس فارطانيان بخلفية متنوعة. عمل نيكولاس تحت إشراف عمدة لوس أنجلوس السابق، أنطونيو فيلارايغوسا، كمحلل للتجارة الدولية. خلال فترة عمله في مكتب العمدة، تعاون مع أوستن بيوتْنر لجذب الاستثمارات الأجنبية المباشرة، متعاملًا مع مستثمرين مثل الشيخ محمد بن راشد آل مكتوم من دبي، ورئيس وزراء إنجلترا السابق توني بلير، ونائب الرئيس الأول لشركة Forever 21 كريستوفر لي، وساعد في تأمين مصنع لتصنيع سيارات BYD الكهربائية في لوس أنجلوس. بعد مغادرته المجال العام، انضم نيكولاس إلى مركز لوسكين للابتكار، وهو مركز أبحاث اقتصادي، حيث شارك في صياغة سياسة نظام Feed-in-Tariff (FiT) للضرائب على الطاقة الشمسية على الأسطح التجارية. وقد تم اعتماد هذا النظام بالإجماع من قبل مدينة لوس أنجلوس وإدارة المياه والكهرباء. خلال السنوات الـ13 الماضية، عمل نيكولاس في قطاع الرعاية الصحية، مستكشفًا طرقًا فعّالة لإحداث تغييرات داخل الصناعة، وشغل مناصب تنفيذية في مجالي الأدوية والمختبرات السريرية.

We’re here to support your health and your business Contact Information Our Locations : Dawah Holdi Company 26 Galal El-Din El-Desouky Street – 1st Floor – Apartment 3 – Almaza – Cairo Dawah Gypto Company Plot 27 – Industrial Zone – Khanka – Abu Zaabal – Qalyubia Governorate2nd Floor – Inside the premises of Gypto Company New York 125 Michael Drive, Suite 106 Syosset, NY 11719 Get in Touch with Our Team : 01200060637 Email: info@dawahpharma.com +1 347 669 1693 Social Media: Submit